Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2009 February 2; 119(2): 399–407.
Published online 2009 January 19. doi:  10.1172/JCI34665
PMCID: PMC2631290

PKCα regulates platelet granule secretion and thrombus formation in mice


Platelets are central players in atherothrombosis development in coronary artery disease. The PKC family provides important intracellular mechanisms for regulating platelet activity, and platelets express several members of this family, including the classical isoforms PKCα and PKCβ and novel isoforms PKCδ and PKCθ. Here, we used a genetic approach to definitively demonstrate the role played by PKCα in regulating thrombus formation and platelet function. Thrombus formation in vivo was attenuated in Prkca–/– mice, and PKCα was required for thrombus formation in vitro, although this PKC isoform did not regulate platelet adhesion to collagen. The ablation of in vitro thrombus formation in Prkca–/– platelets was rescued by the addition of ADP, consistent with the key mechanistic finding that dense-granule biogenesis and secretion depend upon PKCα expression. Furthermore, defective platelet aggregation in response to either collagen-related peptide or thrombin could be overcome by an increase in agonist concentration. Evidence of overt bleeding, including gastrointestinal and tail bleeding, was not seen in Prkca–/– mice. In summary, the effects of PKCα ablation on thrombus formation and granule secretion may implicate PKCα as a drug target for antithrombotic therapy.


The PKC family comprises 10 isozymes grouped into 3 classes: conventional (α, βI, βII, γ), novel (δ, ε, η/L, θ), and atypical (ζ, ι/λ) (1). PKCs have long been known to play major roles in a number of platelet processes (2), most importantly aggregation and secretion, in which stimulation of platelets with diacylglycerol (DAG) or phorbol ester can induce aggregation and agonist-induced secretion can be prevented by broad spectrum pharmacological inhibition of PKC isoforms (36). Recently, it has been shown pharmacologically that PKC isoforms may exert a dual-control role in thrombus formation by mediating secretion and integrin activation under flow while also suppressing phosphatidylserine exposure and subsequent thrombin generation and coagulation (7).

At least 4 PKC isoforms (α, β, δ, θ) are expressed in human platelets (814), and it is becoming clear that each isoform may play a different role in platelet function. Using genetic and pharmacological approaches, we have shown PKCδ to play a negative role in regulating filopodia formation and platelet aggregation in response to collagen through a functional interaction with the actin regulatory protein VASP (15, 16). Using biochemical approaches, PKCα has been identified as an essential factor in positively regulating α-granule and dense-granule secretion in platelets (17) as well as platelet aggregation (18). We have recently shown, using biochemical and pharmacological approaches, that 2 tyrosine kinases, Syk and Src, physically and functionally interact with PKCα to regulate each other and cellular activities in platelets (19). It is now important that the function of PKCα in platelets be addressed definitively by a genetic approach.

Genetic and molecular approaches have revealed a wide range of roles for PKCα in other cell types. Cell proliferation, differentiation, apoptosis, motility, and adhesion are all regulated by PKC (1, 20), with consequent roles for PKCα in regulation of tumor progression. Although there is evidence that in some tumors, PKCα may have a suppressor role (21, 22), in the majority of cases, PKCα expression and activity are higher in tumors than in normal tissues (23, 24) and PKCα activity promotes a more aggressive phenotype in breast cancer cells, with an increased metastatic potential (2527). PKCα has therefore become a major target for therapeutic intervention in various cancers (28). In immune regulation, PKCα mediates T cell–dependent interferon generation (29) and is also critical for T cell receptor downregulation (30). Insulin signaling to PI3K and subsequently to glucose transport is enhanced in mice lacking PKCα (31), suggesting a negative feedback role for PKCα in metabolic processes. Finally, in the heart, PKCα regulates cardiac contractility and Ca2+ handling in myocytes, and deficiency of PKCα protects against heart failure induced by pressure overload and against dilated cardiomyopathy (32).

In a recent elegant study reconstructing the signaling pathway regulating platelet integrin αIIbβ3 in a nucleated cell system, it was shown that expression levels of PKCα equivalent to those found in platelets are required for activation of the integrin through the Rap1 pathway (33). This is in agreement with previous biochemical evidence suggesting an essential role for PKCα in regulating integrin (18). Importantly also, genome-wide association analysis of coronary artery disease revealed a cluster of SNPs in the PRKCA gene, with a maximal P value association of just over 10–3 (SNP rs12600582) (34, 35). This analysis marks the gene as one requiring further phenotypic analysis. It was essential to identify definitively by a genetic approach the role of PKCα in regulating platelet function and thrombus formation. Here, we report that genetic ablation of PKCα in platelets reveals nonredundant roles in regulating platelet dense-granule biogenesis and exocytosis and in the control of thrombus formation in vitro and in vivo.


Major role for PKCα in inside-out regulation of αIIbβ3 but no significant role in outside-in signaling through this integrin.

The PKC family of kinases has been implicated in agonist-induced αIIbβ3 integrin activation (36), and although an elegant reconstruction study showed a critical role for PKCα in regulating the integrin (33), an involvement of PKCα in this event in platelets has not yet been addressed directly and definitively. Here, we report for what we believe is the first time in platelet functional and thrombosis analysis, data from a mouse gene knockout lacking PKCα. Supplemental Figure 1 (supplemental material available online with this article; doi: 10.1172/JCI34665DS1) shows baseline data demonstrating lack of expression of PKCα but normal expression of other platelet PKCs (β, δ, and θ) in Prkca–/– platelets. Figure Figure1A1A shows that both collagen-related peptide (CRP) (5 μg/ml) and thrombin (1 U/ml) produced significantly greater αIIbβ3 activation in WT platelets compared with Prkca–/–. This suggests that PKCα is a major regulator of inside-out signaling to αIIbβ3, although the residual response in the absence of PKCα suggests a component independent of this kinase. By way of control, Supplemental Figure 2 shows no significant difference in surface expression of αIIb (CD41) in Prkca–/– versus WT irrespective of activation state of the platelets and irrespective of agonist (CRP or thrombin).

Figure 1
PKCα plays a major role in regulating inside-out signaling to integrin αIIbβ3 but no significant role in outside-in signaling or in adhesion to fibrinogen or collagen.

It has been shown recently that PKCβ and PKCθ play critical roles in regulating outside-in signaling from αIIbβ3 (37, 38). Hence, in mouse platelets lacking either PKCβ or PKCθ, cell spreading on fibrinogen-coated surfaces was ablated. Additionally, we had recently shown that absence of PKCδ caused platelets to spread on CRP- or collagen-coated surfaces with markedly more sustained generation of filopodia than WT control platelets. It was important therefore to assess the role of PKCα in adhesion and spreading on either fibrinogen or CRP, and so we measured the number and surface area of adherent platelets by differential interference contrast (DIC) microscopy over a 40-minute period. Figure Figure1,1, B–D, shows that platelets lacking PKCα had no significant defect in their ability to spread on either fibrinogen-coated or CRP-coated surfaces, and importantly in the case of CRP, there was no evident sustained development of filopodia. In addition, although Figure Figure1,1, C and D, shows a trend toward decreased adhesion of platelets to both surfaces in Prkca–/–, significance was achieved only at a single time point (30 minutes; 90.31 ± 6.9 platelets/field of view in WT compared with 62.18 ± 5.6 platelets/field of view in Prkca–/– mice; mean ± SEM, P < 0.05) in platelets adherent to fibrinogen.

PKCα is a major regulator of dense- and α-granule secretion.

Figure Figure2A2A shows that Prkca–/– platelets also exhibit a marked reduction in CRP- and thrombin-induced ATP secretion relative to WT controls (40.9 ± 7.0 nM ATP in WT vs. 8.9 ± 3.4 nM ATP in Prkca–/– for CRP, P < 0.05; and 61.1 ± 14.7 nM in WT vs. 10.8 ± 5.7 in Prkca–/– for thrombin, P < 0.05). The defect in granule secretion was not restricted to dense granules, however, but also involved regulation of α-granules. Stimulation with CRP induced P selectin surface expression in WT platelets, which was significantly greater than that in Prkca–/– platelets (411.9% ± 145.3% over basal in WT vs. 130.7% ± 14.6% over basal in Prkca–/–). A similar marked knockdown of P selectin exposure was observed after thrombin activation (Figure (Figure2B)2B) (705% ± 235.7% in WT vs. 113.9% ± 5.5% in KO; P < 0.05), suggesting that PKCα plays a major role in platelet α-granule and dense-granule release.

Figure 2
Key role for PKCα in secretion of dense granules and α-granules.

It has been demonstrated that SNAP23, a member of SNARE traffic and fusion protein complex, undergoes PKC-dependent phosphorylation during agonist-stimulated platelet degranulation, and in vitro PKCα was one of the isoforms able to phosphorylate recombinant SNAP23 (39). We therefore assessed the contribution of PKCα to phosphorylation of SNAP23 on Ser95, the site reported to be phosphorylated following thrombin stimulation (40). Supplemental Figure 3A shows a time course of phosphorylation of SNAP23 from WT mouse platelets. This time course correlated well with release of ATP from those platelets stimulated with thrombin. We then showed that both CRP and thrombin activation led to a potent increase in SNAP23 phosphorylation at Ser95, which was considerably although not completely inhibited by absence of PKCα (Supplemental Figure 3B). PKCα-mediated phosphorylation of SNAP23 may therefore play a role in regulating secretion or SNARE recycling.

It was possible that the secretory defect seen in Prkca–/– platelets may be a result of a granule developmental problem. Transmission electron microscopy analysis of platelet ultrastructure showed an abnormality in the number of dense granules in Prkca–/– platelets, characterized by an approximately 3.7-fold reduction compared with WT platelets (Figure (Figure3).3). Dense-granule biogenesis in megakaryocytes or peripheral distribution during proplatelet development could be the key points of regulation by PKCα, and this may additionally explain the major defect in dense-granule secretion seen in Prkca–/– platelets. Transmission electron microscopy quantification of α-granule numbers, however, did not detect any substantial difference between WT and Prkca–/– platelets, indicating that the defect in α-granule secretion is due to an essential role played by PKCα in regulation of secretion of these granules rather than their biogenesis.

Figure 3
PKCα regulates dense-granule but not α-granule biogenesis.

Platelet aggregation deficit in Prkca–/– platelets is rescued by exogenous ADP.

It was now important to determine whether the deficits in secretion and activation of integrin αIIbβ3 would translate into functional deficits in platelet aggregation and thrombus formation. Figure Figure44 shows concentration-response relationships for platelet aggregation activated by CRP (Figure (Figure4A)4A) or thrombin (Figure (Figure4B).4B). At submaximal concentrations of either agonist, absence of PKCα had a marked effect upon the aggregation response, such that the aggregation responses to 1.25 μg/ml CRP or 0.065 U/ml thrombin were almost ablated in Prkca–/– platelets. Importantly, however, responses may be effectively rescued by addition of exogenous ADP (10 μM) simultaneously with CRP or thrombin. This indicates that the important functional deficit in Prkca–/– platelets is the lack of dense-granule secretion. The effect upon aggregation was also relative, since higher concentrations of either CRP or thrombin were able to restore aggregations to wild-type values.

Figure 4
ADP rescues deficient aggregation responses to CRP or thrombin in Prkca–/– platelets.

Pharmacological inhibition of PKCβ reveals redundancy with PKCα for regulation of platelet aggregation.

Given that higher concentrations of agonists are capable of overcoming the aggregation deficits seen in the absence of PKCα, it was important to address whether there may be functional redundancy between PKCα and its closely related family member PKCβ. To assess this possibility, we preincubated platelets with the inhibitor of classical PKC isoforms Gö6976 at its maximally effective concentration (1 μM), which completely abrogated CRP-induced aggregation both in WT and Prkca–/–mouse platelets (Figure (Figure5A).5A). This confirmed an indispensable role for classical PKC isoforms in glycoprotein VI–mediated (GPVI-mediated) aggregation and suggested a potential redundancy between PKCα and PKCβ in regulating aggregation. This redundancy was demonstrated by using the PKCβ-selective inhibitor LY333531 (ruboxistaurin), which at a maximally effective concentration (10 μM) had no significant effect upon aggregation of WT platelets to CRP but was markedly inhibitory to this response in platelets lacking PKCα (Figure (Figure5B).5B). This was in parallel with thrombin (0.5 U/ml), for which addition of 10 μM LY333531 had no effect upon WT platelet aggregation response but markedly inhibited the response in Prkca–/– platelets (data not shown). Interestingly, for weaker agonists such as the thromboxane analogue U46619, aggregation was ablated in platelets lacking PKCα, although shape change in these platelets was unaffected (Figure (Figure5C).5C). This is consistent with pharmacological data that show a critical role for PKC in platelet aggregation induced through the thromboxane receptor system (41). These data therefore suggest that for weak agonists, PKCα plays an essential role, whereas redundancy between PKCα and PKCβ exists for strong agonists in regulating the platelet aggregation response.

Figure 5
Combined pharmacological and genetic approaches reveal redundancy between PKCα and PKCβ for regulation of platelet aggregation.

Ablation of PKCα markedly attenuates thrombus formation in vitro and in vivo.

Finally, it was important to determine the role played by PKCα in thrombus formation both in vitro and in vivo. Figure Figure6A6A shows a major role for PKCα in vitro in mediating this function, where the images reveal no reduction in primary adhesion of platelets to the collagen-coated surface, consistent with the absence of effect upon static adhesion shown in Figure Figure1,1, but a marked reduction in aggregated platelet thrombus formation on top of the initially adherent cells. In order to confirm in a quantitative manner the lack of effect of PKCα ablation on primary adhesion, fluo-4–labeled platelets were added to the blood and used for measurements of platelet adhesion during flow over a collagen surface, as we previously described (42). Fluo-4–labeled cells flowing across the field of view were counted, and the percentage of these cells that adhered stably (adherent for >20 seconds) was estimated. At a shear rate of 1000 s–1, 81.7% ± 3.6% of WT and 78.1% ± 3.0% of Prkca–/– platelets became stably adherent (mean ± SEM, n = 5; P > 0.05), indicating no significant difference in initial stable adhesion to collagen. Also, in order to confirm that in the absence of PKCα, the 3D buildup of thrombus formation was markedly impaired, reconstructed images were generated from confocal Z-stacks (as described in Methods) and platelet aggregate (thrombus) volumes estimated. The mean volume of representative platelet aggregates on the coverslips after flow at 1000 s–1 was 570 ± 168 μm3 and 72.3 ± 7.4 μm3 for WT and Prkca–/– blood, respectively (mean ± SEM, n = 5; P < 0.05). The major secretory defect seen in Prkca–/– platelets was likely to be responsible for the impairment of thrombus formation, since addition of ADP (20 μM) to the blood in the flow chamber was capable of rescuing thrombus formation (Figure (Figure6,6, A and B). This indicated that the thrombotic process under flow conditions markedly relies upon the contribution to secretion made by PKCα.

Figure 6
PKCα regulates thrombus formation in vitro.

It was important finally to assess the role in vivo of PKCα in regulating thrombus formation. Figure Figure77 shows data reflecting application of a laser-induced endothelial injury model in cremaster muscle arterioles, described previously (43, 44). A marked difference is evident between WT controls and mice lacking PKCα (Figure (Figure7),7), since in the absence of PKCα, thrombus formation is delayed and results in fewer accumulated platelets (see Supplemental Videos 1 and 2). Importantly, however, the ability of Prkca–/– to undergo normal hemostasis was demonstrated by the lack of alteration in tail-bleed time (Figure (Figure7E)7E) and by the lack of any fecal occult blood (data not shown). This may indicate that compensatory mechanisms are sufficient to allow normal hemostasis but are not sufficient to support normal thrombus formation and may reflect the observation that Prkca–/– platelets adhere normally to collagen under static and flow conditions (Figures (Figures11 and and6)6) but have a marked reduction in subsequent platelet-platelet interaction (as evidenced by the lack of thrombus accumulation shown in Figure Figure6A). 6A).

Figure 7
In vivo thrombus formation is impaired in the absence of PKCα, but tail bleeding time is normal.


Platelets play a central role in mediating atherothrombosis and are therefore the target of numerous therapies aimed at reducing their activity, particularly in the prevention of coronary artery thrombosis in heart attacks (45). PKC is established, largely by pharmacological studies, as a major regulator of multiple platelet activities (2), and it is increasingly clear that the different isozymes of PKC expressed in platelets perform distinct functions. There is a difficulty of interpretation of data from some pharmacological studies, however, because of the lack of selectivity of the reagents available to target specific PKC isozymes. Here, we used a genetic approach to demonstrate definitively, for what we believe is the first time, the role played by PKCα in regulating platelet function and thrombus formation. Importantly, the study revealed a key role for PKCα in regulating granule biogenesis and exocytosis, which was essential for thrombus formation, since ablation of thrombus formation in Prkca–/– platelets could be rescued by addition of exogenous ADP. The findings reveal PKCα to be a potential drug target for antithrombotic therapy, since selective inhibitors would exert a major effect upon thrombus formation while sparing primary platelet adhesive functions.

It has recently been shown pharmacologically that PKC isoforms exert dual control of thrombus formation by mediating secretion and integrin activation under flow while suppressing phosphatidylserine exposure and subsequent thrombin generation and coagulation (7). There is incomplete and largely indirect evidence that, of the various isoforms of PKC expressed in platelets, PKCα plays a role in regulation of integrin αIIbβ3 activation (36). The study by Han et al. (33) elegantly showed that PKCα was required for integrin αIIbβ3 activation in a reconstituted cell system rather than in the platelet. The study by Tabuchi et al. (18) used an in vitro permeabilized platelet system to investigate receptor-independent calcium-mediated activation of platelet aggregation. Although this latter study demonstrated that added purified PKCα was able to support a calcium-induced platelet aggregation response, the approach has limitations in that receptor-mediated activation is lost. Nonetheless, these studies provided indications that PKCα may regulate platelet integrin activation and aggregation, and it was therefore essential to perform a genetic-based definitive study of the role played by PKCα in mediating these events.

The marked knockdown in activation of integrin αIIbβ3 in response either to thrombin or CRP in platelets lacking PKCα paralleled a deficit in the ability of these platelets to undergo aggregation at submaximal concentrations of agonist. This was consistent with the impaired ability of Prkca–/– platelets to form a thrombus in blood flowing over a collagen-coated surface. The effect on aggregation could, however, be overcome by increasing the concentration of agonist, and the reasons for this may derive from several factors. First, it is known that integrin αIIbβ3 activation in response to strong agonists is in part regulated independently of PKC (3, 46). Further, studies with integrin blockers have shown that not all αIIbβ3 receptors are required to be activated (e.g., by the PKC-independent pathway) for a full platelet aggregation response in the platelet aggregometer (47). Thus, it may be possible to achieve a maximal aggregation response with a markedly reduced expression of activated integrin. In contrast, in thrombus formation in flowing whole blood, stable platelet aggregation critically depends on limited levels of autocrine-produced ADP and hence limited and reversible integrin activation (48). Under these more physiological conditions, the number of activated integrin receptors may be low, and therefore the marked reduction in integrin activation seen in Prkca–/– platelets may cause a significant reduction in the ability of platelets to form thrombi. Additionally, we provide evidence for redundancy between PKCα and PKCβ in Figure Figure5,5, which shows that selective inhibition of PKCβ only significantly attenuated aggregation responses in Prkca–/– platelets, not WT platelets, indicating redundant functions of these 2 isoforms. It is also significant to note that in assays for occult blood in feces, no gastrointestinal bleeding was detected in either WT (n = 5) or Prkca–/– (n = 6) mice. Together with the data shown in Figure Figure7,7, where no difference in tail bleeding time is seen in Prkca–/– compared with WT controls, this also implies redundancy of signaling molecules for regulation of hemostasis in vivo.

There is significant contribution to the effects of PKCα ablation on aggregation and thrombus formation by regulation of granule secretion, since these processes greatly rely upon autocrine ADP release (49). Clearly, both dense- and α-granule secretion are markedly disrupted in platelets lacking PKCα, and evidence that this is functionally critical is provided by the rescue experiments depicted in Figure Figure44 for aggregation and Figure Figure66 for in vitro thrombus formation, where addition of exogenous ADP recovers the deficits in these responses seen in Prkca–/– platelets.

The role of unspecified PKC isoforms as a family in the regulation of secretion has been shown pharmacologically by several groups (36). The role of the PKCα isoform in agonist-independent secretion has been demonstrated previously in an artificial permeabilized platelet system (17). Although valuable to indicate the role of PKCα, it was important to address the issue by a definitive genetic approach. Indeed, the only study to date to address specific PKC isoform function in secretion in platelets in a combined genetic and pharmacological approach had shown a major discrepancy in results obtained by the 2 approaches for PKCδ. Pula et al. (15) showed that genetic ablation of PKCδ had no significant effect upon dense-granule secretion, whereas in that study and previous studies (9, 16), the PKCδ-selective inhibitor rottlerin had been shown to enhance dense-granule secretion in response to collagen and alboaggregin, operating through the GPVI receptor. The present results provide direct evidence that PKCα is a major regulator of secretion of α-granules, since P selectin expression is reduced almost to basal levels in Prkca–/– platelets in response either to CRP or thrombin. Importantly, we show that α-granule numbers are equivalent between Prkca–/– and WT platelets and therefore the secretion defect for this granule type reflects a genuine deficiency in the secretory pathway. For dense granules, this study shows an additional knockdown in numbers of granules in Prkca–/– platelets. This suggests a role for PKCα in biogenesis of dense granules and is therefore an area that requires further analysis. A number of different elements of the secretory machinery, including SNAP23, SNAP25, Munc18a and Munc18b, syntaxin 2, and Rab6, have been reported to be PKC substrates (40, 5052), and therefore their phosphorylation may influence secretion. In this study then, phosphorylation of SNAP23 serves as a potential marker for these events and may contribute functionally to the process of secretion. However, although SNAP23 phosphorylation on Ser95 is markedly reduced in Prkca–/– platelets and this may play a role in regulating α-granule secretion, its role in dense-granule secretion cannot be clarified from this study.

In summary, we have shown PKCα to play major roles in regulating platelet secretion of α-granules, biogenesis and secretion of dense granules, regulation of integrin αIIbβ3, and thrombus formation in vitro and in vivo. PKCα also regulates platelet aggregation, although the defect in Prkca–/– platelets is relative, since high concentrations of agonists overcome the deficit and there is evident redundancy of the action of PKCα with the other expressed classical PKC isoform in platelets, PKCβ. PKCα plays no significant role in regulating adhesion of platelets to collagen-coated surfaces under static or flow conditions and does not regulate platelet spreading response or outside-in signaling through integrin αIIbβ3. It could be argued that, because PKCα is the most highly expressed of the PKC isoforms in platelets, its role in platelets may be wide ranging and effectively mask that of other PKC isoforms that are expressed at lower levels. The evidence presented here, however, suggests highly specific roles for PKCα, since, for instance, its absence has no significant effect upon platelet adhesion and spreading on collagen but markedly suppresses thrombosis. Additionally, if PKCα were so predominant functionally in platelets, knockout of the other PKC isoforms would be predicted not to have functional effects. This is clearly not the case, since we have shown absence of PKCδ to enhance platelet responses to collagen through enhanced filopodia formation (15) and we have more recently shown absence of PKCθ to enhance α-granule secretion and integrin αIIbβ3 activation in response to GPVI agonists (53). Shattil’s group has also shown absence of PKCs β and θ to ablate outside-in signaling through integrin αIIbβ3 (37, 38). These data therefore demonstrate specific functional roles for the different PKC isoforms, including for PKCα in regulating secretion in particular, such that redundancy of activity is not apparent for specific functions.

Genome-wide association analyses of major human diseases have been conducted recently, based upon technical advances in high throughput microarray analyses of SNPs. These studies are introducing major new leads in genes that may be related to disease, and although PKCα is not in the top ranking of genes associated with coronary artery disease, a cluster of SNPs in this gene with a maximal P value of just over 10–3 (SNP rs12600582, intronic, minor allele frequency of 0.233 in Europeans) (34, 35) may indicate some significance in this disease of polygenic cause. For these reasons, PKCα may represent a drug target for antithrombotic therapy, with inhibitors exerting an effect upon thrombus formation but sparing primary platelet adhesive functions. PKCα is already a target for the drug aprinocarsen, an antisense oligonucleotide therapy used in the treatment of specific neoplastic conditions (54, 55), and it will now be important to assess whether this or other small molecule–based approaches may represent opportunities in the development of platelet-based antithrombotic drugs in the management of coronary artery disease and other arterial thrombotic diseases.



CRP was from Richard Farndale (University of Cambridge, Cambridge, United Kingdom). Thrombin, BSA, ADP, protein G-Sepharose, and fibrinogen were purchased from Sigma-Aldrich. Complete Mini Protease Inhibitor Tablets were from Roche Applied Science. Secondary HRP-conjugated anti-rabbit antibody was obtained from Santa Cruz Biotechnology Inc. SNAP23 (P-T95) antibody was a generous gift from Paul Roche (NIH). JON/A (anti-αIIbβ3) and WugE9 (anti–P selectin) antibodies were from Emfret Analytics. PE-conjugated anti-CD41 antibody and its isotype-matched control, PE-conjugated rat IgG1, were from AbD Serotec. Isoform-specific anti-PKC mouse monoclonal antibodies were from BD Biosciences. LY333531 was supplied by A.G. Scientific Inc. (Fluorochem Ltd.), U46619 was from ALEXIS Biochemicals, Gö6976 was from Calbiochem, and CHRONO-LUME reagent came from Chrono-log (Labmedics). The P2Y12 antagonist AR-C69931MX was a gift from AstraZeneca. The P2Y1 antagonist MRS2500 was from Tocris Bioscience.

Platelet preparation.

Mice were bred and maintained in the University of Bristol animal facility in accordance with United Kingdom Home Office regulations. All procedures were undertaken with United Kingdom Home Office approval in accordance with the Animals (Scientific Procedures) Act of 1986 (project license numbers: 40/2212, 40/2749 and 30/2386). Prkca–/– mice were generated as previously described (32). Blood was drawn by cardiac puncture under terminal anesthesia into acid citrate dextrose (20 mM citric acid, 110 mM sodium citrate, 5 mM glucose), 1:7 ratio, v/v. Platelets were prepared as previously described (15). In brief, blood was diluted with 250 μl of modified Tyrode’s-HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, and 1 mM MgCl2, pH 7.3) and centrifuged at 180 g for 6 minutes at room temperature. Platelet-rich plasma was removed, and platelets were isolated by centrifugation at 550 g for 6 minutes in the presence of PGE1 (140 nM) and indomethacin (10 μM). Pelleted platelets were resuspended to the required density in modified Tyrode’s-HEPES buffer and rested for 30 minutes at 37°C in the presence of 10 μM indomethacin prior to stimulation.

Platelet aggregation.

Platelets were resuspended in Tyrode’s–HEPES buffer at a final concentration of 2 × 108 per ml. Platelets were preincubated with different inhibitors or vehicle solution (0.1% Me2SO final concentration) for 10 minutes at 37°C, and aggregation of agonist-stimulated platelets was monitored in an optical aggregometer (Chrono-log; Labmedics) at 37°C, with continuous stirring at 800 rpm.

Flow cytometry.

Two-color analysis of mouse platelet activation was conducted using PE-conjugated JON/A, an antibody that preferentially binds to the active form of αIIbβ3 integrin, and with a FITC-conjugated antibody specific for CD62P (P selectin). 25 μl of washed platelets (4 × 107/ml in Tyrode’s-HEPES buffer supplemented with 1 mM CaCl2 and 0.35% BSA) was mixed with 10 μl of antibody and subsequently stimulated either with 5 μg/ml CRP or 1 U/ml thrombin for 15 minutes at room temperature. The reaction was stopped by addition of 400 μl ice-cold PBS, and samples were analyzed within 30 minutes. For estimation of surface expression levels of total αIIbβ3 integrin, CD41 was stained with PE-conjugated anti-CD41. Flow cytometry was performed on a FACSCalibur flow cytometer (BD Biosciences), using CellQuest version 3.1f software (BD Biosciences), and a total of 20,000 events per sample were collected.

Measurement of ATP secretion.

ATP secretion was measured using CHRONO-LUME reagent according to the manufacturer’s protocol. 5 μl luciferase-luciferin was added directly to the platelets, which were being continually stirred (1000 rpm), and 5 μg/ml CRP or 1 U/ml thrombin was added to activate platelets for 1 minute. The luminescence intensity was measured at a setting of ×0.05.

Platelet spreading and adhesion assay.

Coverslips were coated with either 0.1 mg/ml fibrinogen or 50 μg/ml CRP and left overnight, followed by nonspecific blocking step with 2% BSA for 1 hour. Platelets were resuspended to 2 × 107/ml in modified Tyrode’s-HEPES buffer, and 500 μl was dispensed onto the coverslip mounted in a live-cell microscopy chamber. Adhesion and spreading of platelets was observed by differential interference contrast (DIC) microscopy, with a wide-field DM IRB microscope attached to an ORCA ER camera (63×/1.40 NA oil objective) (Leica). Five images in different random parts of the coverslip area were taken at 15, 30, and 45 minutes and processed with OpenLab 4.03 (Improvision) and Adobe Photoshop software. The surface area and number of adherent platelets was estimated using ImageJ software (


For stimulated samples, 2 × 108/ml of washed platelets were activated with 5 μg/ml CRP or 1 U/ml thrombin in the presence of 2 mM CaCl2 for 3 minutes and solubilized in Laemmli sample buffer. Proteins were resolved by electrophoresis in 9.5% (for PKC isoform estimation) or 16% (for SNAP23 Ser95 phosphorylation estimation) SDS-PAGE. Samples were then transferred to PVDF membranes, blocked with 10% BSA, and subjected to immunoblotting with anti-PKCα, -β, -θ or -δ antibodies, SNAP antibody, or phospho–SNAP23-Ser95 antibody.

Thrombus formation under flow in vitro.

Flow-induced thrombus formation was assessed basically as described before (56). Heparin/D-phenylalanyl-prolyl-arginyl chloromethyl ketone–anticoagulated (Heparin/PPACK-anticoagulated) mouse blood was passed over immobilized collagen through a parallel plate perfusion chamber at a shear rate of 1000 s–1 for 4 minutes. Where indicated, ADP (200 μM in saline) was coinfused at a 10% rate immediately before the blood reached the flow chamber. For each perfusion surface, phase-contrast images from 10 random microscopic fields were collected. Surface coverage was analyzed using Image-Pro software, version 4.1 (Media Cybernetics). The average percentage area covered by adherent platelets was measured by automated setting of masks for the ranges of gray levels corresponding to the presence of platelets and thrombi. For each image, the (blinded) observer needed to approve the mask settings. Averaged pixel fractions of the masks from 10 images were considered as a best estimate of the surface area coverage with thrombi.

Aggregate volume was also estimated by confocal laser scanning microscopy, using a Bio-Rad 2100 multiphoton system (Bio-Rad Laboratories), as described before (57). Platelet aggregates that formed on collagen (4 minutes, shear rate 1000 s–1) were postlabeled with FITC–anti-mouse CD62 mAb (1:100). Confocal stacks were recorded for measurement of the volume of individual platelet aggregates. Analysis of confocal images (gray level bit maps) and 3D reconstruction of images were with LaserPix software (Media Cybernetics).

Detection of occult fecal blood.

The presence of occult fecal blood was detected by Hemdetect (DIPRO, supplied by Autogen Bioclear) on freshly obtained stool samples.

Electron microscopy.

Platelet-rich plasma was collected and spun at 590 g for 5 minutes. Supernatant was removed from the platelet pellet, and the pellet was fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (PB) (pH 7.4). The pellet was washed in PB and then incubated in 1% osmium tetroxide in PB for 30 minutes. After washing in PB and deionized water, the pellet was incubated in 3% uranyl acetate in deionized water for 30 minutes. After washing with deionized water, the pellet was dehydrated in a graded series of increasing amounts of ethanol (70%, 80%, 90%, 96%, 100%, and 100%, with each step lasting for 10 minutes). After removal of the 100% ethanol, the pellet was incubated with pure Epon for 2 hours at room temperature. Thereafter, the Epon was replaced with fresh Epon, and this was hardened overnight in a 60°C oven. Ultrathin counterstained sections were imaged on a Philips CM100 equipped with a side-mount MegaView III camera (Olympus Soft Imaging Solutions).

To determine the dense-granule and α-granule content, total numbers of granules in equivalent-sized fields of view were counted. For each genotype, 25–30 randomly chosen fields of view were examined. All microscopic images were taken at the same magnification (×19,000), and the number of cells per field of view between WT and Prkca–/– preparations were equivalent.

Analysis of bleeding time.

Experiments were conducted on 25–35 g male and female mice. Mice were anesthetized (75 mg/kg ketamine and 1 mg/kg medetomidine intraperitoneally), and a transverse incision was made with a scalpel at a position where the diameter of the tail was 2.25 to 2.5 mm. The tail was immersed in normal saline (37°C) in a hand-held test tube, and the time from incision to cessation of bleeding was recorded.

Intravital microscopy of thrombus formation in vivo.

Intravital microscopy was performed essentially as described previously (44). Experiments were conducted on 25–30 g male Prkca–/– mice and their littermate-matched control WTs. Anesthesia was induced by intraperitoneal ketamine (100 mg/kg Vetalar; Pharmacia & Upjohn Ltd.) and 2% xylazine (20 mg/kg; Millpledge Pharmaceuticals). The left cremaster muscle was exteriorized and spread flat over an optically clear coverslip and continuously superfused. High-speed intravital microscopy experiments were performed as previously described by Falati et al. (43).

Platelets were labeled fluorescently with Alexa Fluor 488–conjugated goat anti-rat antibody (Molecular Probes) and rat anti-murine CD41 antibody (BD Biosciences — Pharmingen) infused via a carotid cannula. Thrombi were induced in arterioles with a diameter of 25–35 μm by a nitrogen ablation laser (MicroPoint; Photonic Instruments), which was introduced through the microscope objective. Bright field and fluorescent images were captured simultaneously for 4–5 minutes, and multiple thrombi were generated with a distance of at least 200 μm between them and upstream of previous injuries. The integrated intensity value for the growing thrombus was plotted against time and peak size of thrombus, and time taken to reach peak was determined.


Statistical analyses were carried out on raw data using unpaired, 2-tailed Student’s t test, and P < 0.05 was considered statistically significant. Values are expressed as mean ± SEM. For all data, n indicates number of mice tested.

Supplementary Material

Supplemental video 1:
Supplemental video 2:
Supplemental data:


We thank Elizabeth Aitken for expert technical assistance supporting this work. The authors would like to thank AstraZeneca for the kind gift of AR-C69931MX. SNAP23 (P-T95) antibody was a generous gift from Paul Roche (NIH). We thank Mark Jepson and Alan Leard for their assistance within the School of Medical Sciences Cell Imaging Facility. We are also grateful to Gini Tilly and Deborah Carter for their assistance with electron microscopy. We thank Ian Day and Tom Gaunt (University of Bristol) for valuable discussions and advice regarding genome-wide–association analyses. We thank Majd Protty, University of Birmingham, for help with analysis of in vivo thrombosis data. The work was supported by grants from the British Heart Foundation (RG/05/015, FS/04/023, and FS/05/017 to A.W. Poole; CH/03/003 to S.P. Watson); the Medical Research Council (MRC-65282 to S.P. Watson); and the NIH (NIHLB HL56652 to S.W. Whiteheart). A.W. Poole is a Biotechnology and Biological Sciences Research Council Research Development Fellow.


Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: CRP, collagen-related peptide; DIC, differential interference contrast; GPVI, glycoprotein VI; PB, phosphate buffer.

Citation for this article: J. Clin. Invest. 119:399–407 (2009). doi:10.1172/JCI34665


1. Parker P.J., Murray-Rust J. PKC at a glance. J. Cell. Sci. 2004;117:131–132. doi: 10.1242/jcs.00982. [PubMed] [Cross Ref]
2. Harper M.T., Poole A.W. Isoform-specific functions of PKC: the platelet paradigm. Biochem. Soc. Trans. 2007;35:1005–1008. doi: 10.1042/BST0351005. [PubMed] [Cross Ref]
3. Shattil S.J., Brass L.F. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J. Biol. Chem. 1987;262:992–1000. [PubMed]
4. Walker T.R., Watson S.P. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem. J. 1993;289:277–282. [PubMed]
5. Toullec D., et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 1991;266:15771–15781. [PubMed]
6. Shattil S.J., et al. Regulation of glycoprotein IIb-IIIa receptor function studied with platelets permeabilized by the pore-forming complement proteins C5b-9. J. Biol. Chem. 1992;267:18424–18431. [PubMed]
7. Strehl A., et al. Dual role of platelet protein kinase C in thrombus formation: Stimulation of pro-aggregatory an suppression of procoagulant activity in platelets. J. Biol. Chem. 2007;282:7046–7055. doi: 10.1074/jbc.M611367200. [PubMed] [Cross Ref]
8. Crosby D., Poole A.W. Interaction of Bruton’s tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases. J. Biol. Chem. 2002;277:9958–9965. doi: 10.1074/jbc.M108965200. [PubMed] [Cross Ref]
9. Murugappan S., Tuluc F., Dorsam R.T., Shankar H., Kunapuli S.P. Differential role of PKC-delta isoform in agonist-induced dense granule secretion in human platelets. J. Biol. Chem. 2004;279:2360–2367. doi: 10.1074/jbc.M306960200. [PubMed] [Cross Ref]
10. Grabarek J., et al. Identification and functional characterization of protein kinase C isozymes in platelets and HEL cells. J. Biol. Chem. 1992;267:10011–10017. [PubMed]
11. Crabos M., Imber R., Woodtli T., Fabbro D., Erne P. Different translocation of three distinct PKC isoforms with tumor-promoting phorbol ester in human platelets. Biochem. Biophys. Res. Commun. 1991;178:878–883. doi: 10.1016/0006-291X(91)90973-B. [PubMed] [Cross Ref]
12. Baldassare J.J., Henderson P.A., Burns D., Loomis C., Fisher G.J. Translocation of protein kinase C isozymes in thrombin-stimulated human platelets. Correlation with 1,2-diacylglycerol levels. J. Biol. Chem. 1992;267:15585–15590. [PubMed]
13. Wang F., et al. A new protein kinase C, nPKC eta’, and nPKC theta are expressed in human platelets: involvement of nPKC eta’ and nPKC theta in signal transduction stimulated by PAF. Biochem. Biophys. Res. Commun. 1993;191:240–246. doi: 10.1006/bbrc.1993.1208. [PubMed] [Cross Ref]
14. Khan W.A., et al. Selective regulation of protein kinase C isoenzymes by oleic acid in human platelets. J. Biol. Chem. 1993;268:5063–5068. [PubMed]
15. Pula G., et al. PKCδ regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood. 2006;108:4035–4044. doi: 10.1182/blood-2006-05-023739. [PubMed] [Cross Ref]
16. Crosby D., Poole A.W. Physical and functional interaction between PKCδ and Fyn tyrosine kinase in human platelets. J. Biol. Chem. 2003;278:24533–24541. doi: 10.1074/jbc.M301847200. [PubMed] [Cross Ref]
17. Yoshioka A., et al. Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha- and dense-core granule secretion in platelets. J. Biol. Chem. 2001;276:39379–39385. doi: 10.1074/jbc.M102933200. [PubMed] [Cross Ref]
18. Tabuchi A., et al. Direct demonstration of involvement of protein kinase Cα in the Ca2+-induced platelet aggregation. . J. Biol. Chem. 2003;278:26374–26379. doi: 10.1074/jbc.M212407200. [PubMed] [Cross Ref]
19. Pula G., Crosby D., Baker J., Poole A.W. Functional interaction of protein kinase Cα with the tyrosine kinases Syk and Src in human platelets. J. Biol. Chem. 2005;280:7194–7205. doi: 10.1074/jbc.M409212200. [PubMed] [Cross Ref]
20. Dempsey E.C., et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279:L429–L438. [PubMed]
21. Oster H., Leitges M. Protein kinase Cα but not PKCζ suppresses intestinal tumor formation in ApcMin/+ mice. Cancer Res. 2006;66:6955–6963. doi: 10.1158/0008-5472.CAN-06-0268. [PubMed] [Cross Ref]
22. Hara T., et al. Deficiency of protein kinase calpha in mice results in impairment of epidermal hyperplasia and enhancement of tumor formation in two-stage skin carcinogenesis. Cancer Res. 2005;65:7356–7362. doi: 10.1158/0008-5472.CAN-04-4241. [PubMed] [Cross Ref]
23. Michie A.M., Nakagawa R. The link between PKCα regulation and cellular transformation. Immunol. Lett. 2005;96:155–162. doi: 10.1016/j.imlet.2004.08.013. [PubMed] [Cross Ref]
24. Lahn M., et al. Protein kinase Cα expression in breast and ovarian cancer. Oncology. 2004;67:1–10. [PubMed]
25. Masur K., et al. High PKCα and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol. Biol. Cell. 2001;12:1973–1982. [PMC free article] [PubMed]
26. Morse-Gaudio M., Connolly J.M., Rose D.P. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int. J. Oncol. 1998;12:1349–1354. [PubMed]
27. Ways D.K., et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. . J. Clin. Invest. 1995;95:1906–1915. doi: 10.1172/JCI117872. [PMC free article] [PubMed] [Cross Ref]
28. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr. Cancer Drug Targets. 2004;4:327–336. doi: 10.2174/1568009043332961. [PubMed] [Cross Ref]
29. Pfeifhofer C., et al. Defective IgG2a/2b class switching in PKCα–/– mice. J. Immunol. 2006;176:6004–6011. [PubMed]
30. von Essen M., et al. Protein Kinase C (PKC)α and PKCθ are the major PKC isotypes involved in TCR down-regulation. J. Immunol. 2006;176:7502–7510. [PubMed]
31. Leitges M., et al. Knockout of PKCα enhances insulin signaling through PI3K. Mol. Endocrinol. 2002;16:847–858. doi: 10.1210/me.16.4.847. [PubMed] [Cross Ref]
32. Braz J.C., et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nat. Med. 2004;10:248–254. doi: 10.1038/nm1000. [PubMed] [Cross Ref]
33. Han J., et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. . Curr. Biol. 2006;16:1796–1806. doi: 10.1016/j.cub.2006.08.035. [PubMed] [Cross Ref]
34. Samani N.J., et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 2007;357:443–453. doi: 10.1056/NEJMoa072366. [PMC free article] [PubMed] [Cross Ref]
35. The Wellcome Trust Case Control Consortium. . Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678. doi: 10.1038/nature05911. [PMC free article] [PubMed] [Cross Ref]
36. Shattil S.J., Newman P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606–1615. doi: 10.1182/blood-2004-04-1257. [PubMed] [Cross Ref]
37. Soriani A., et al. A role for PKCθ in outside-in αIIbβ3 signaling. . J. Thromb. Haemost. 2006;4:648–655. doi: 10.1111/j.1538-7836.2006.01806.x. [PubMed] [Cross Ref]
38. Buensuceso C.S., et al. Regulation of outside-in signaling in platelets by integrin-associated protein kinase Cβ. J. Biol. Chem. 2005;280:644–653. [PubMed]
39. Polgar J., Lane W.S., Chung S.-H., Houng A.K., Reed G.L. Phosphorylation of SNAP-23 in activated human platelets. J. Biol. Chem. 2003;278:44369–44376. doi: 10.1074/jbc.M307864200. [PubMed] [Cross Ref]
40. Hepp R., et al. Phosphorylation of SNAP-23 regulates exocytosis from mast cells. J. Biol. Chem. 2005;280:6610–6620. doi: 10.1074/jbc.M412126200. [PubMed] [Cross Ref]
41. Quinton T.M., et al. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem. J. 2002;368:535–543. doi: 10.1042/BJ20020226. [PubMed] [Cross Ref]
42. Auger J.M., Kuijpers M.J.E., Senis Y.A., Watson S.P., Heemskerk J.W.M. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J. 2005;19:825–827. [PubMed]
43. Falati S., Gross P., Merrill-Skoloff G., Furie B.C., Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 2002;8:1175–1181. doi: 10.1038/nm782. [PubMed] [Cross Ref]
44. Kalia N., Auger J.M., Atkinson B., Watson S.P. Critical role of FcR γ-chain, LAT, PLCγ2 and thrombin in arteriolar thrombus formation upon mild, laser-induced endothelial injury in vivo. Microcirculation. 2008;15:325–335. doi: 10.1080/10739680701728822. [PubMed] [Cross Ref]
45. Meadows T.A., Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 2007;100:1261–1275. doi: 10.1161/01.RES.0000264509.36234.51. [PubMed] [Cross Ref]
46. Crittenden J.R., et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat. Med. . 2004;10:982–986. doi: 10.1038/nm1098. [PubMed] [Cross Ref]
47. Scarborough R.M., Kleiman N.S., Phillips D.R. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999;100:437–444. [PubMed]
48. Cosemans J.M.E.M., et al. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood. 2006;108:3045–3052. doi: 10.1182/blood-2006-03-006338. [PubMed] [Cross Ref]
49. Remijn J.A., et al. Role of ADP Receptor P2Y12 in platelet adhesion and thrombus formation in flowing blood. . Arterioscler. Thromb. Vasc. Biol. 2002;22:686–691. doi: 10.1161/01.ATV.0000012805.49079.23. [PubMed] [Cross Ref]
50. Morgan A., et al. Regulation of exocytosis by protein kinase C. Biochem. Soc. Trans. 2005;33:1341–1344. doi: 10.1042/BST20051341. [PubMed] [Cross Ref]
51. Fitzgerald M.L., Reed G.L. Rab6 is phosphorylated in thrombin-activated platelets by a protein kinase C-dependent mechanism: effects on GTP/GDP binding and cellular distribution. Biochem. J. 1999;342:353–360. doi: 10.1042/0264-6021:3420353. [PubMed] [Cross Ref]
52. Reed G.L., Houng A.K., Fitzgerald M.L. Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion. Blood. 1999;93:2617–2626. [PubMed]
53. Hall K.J., et al. Genetic analysis of the role of protein kinase Cθ in platelet function and thrombus formation. PLoS ONE. 2008;3:e3277. [PMC free article] [PubMed]
54. Hanauske A.R., Sundell K., Lahn M. The role of protein kinase C-α (PKC-α) in cancer and its modulation by the novel PKC-α-specific inhibitor aprinocarsen. Curr. Pharm. Des. 2004;10:1923–1936. doi: 10.2174/1381612043384376. [PubMed] [Cross Ref]
55. Lahn M., Sundell K., Kohler G. The role of protein kinase C-α in hematologic malignancies. Acta Haematol. 2006;115:1–8. doi: 10.1159/000089458. [PubMed] [Cross Ref]
56. Kuijpers M.J.E., et al. Complementary roles of platelet glycoprotein VI and integrin α2β1 in collagen-induced thrombus formation in flowing whole blood ex vivo. . FASEB J. 2003;17:685–687. [PubMed]
57. Munnix I.C.A., et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler. Thromb. Vasc. Biol. 2007;27:2484–2490. doi: 10.1161/ATVBAHA.107.151100. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation